KRAS Mutation Analysis

Overview

  • EPIC Code:
  • N/A
  • Soft Test Code:
  • PS
  • Send Out Test Code:
  • Soft Path - KRAS2 & KRASV
Alternate Names
  • KRAS Mutation Testing
Clinical Significance

Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing in non-small cell lung cancer may provide prognostic information and predict poor response to EGFR tyrosine kinase inhibitors.


Specimen Collection & Preparation

Specimen Requirements

FFPE tissue: Paraffin block


Transport And Storage

 Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen.


Collection Instructions

Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.


Minimum Volume


Neonatal Volume

Clinical Interpretation

Reference Range:

Refer to Interpretive Results


Methodology:
  • Molecular
Clinical Significance

Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing in non-small cell lung cancer may provide prognostic information and predict poor response to EGFR tyrosine kinase inhibitors.


Production Schedule

Sites Performed
  • NeoGenomics
Departments
  • Sendouts - Pathology
Turn Around Time

7 to 8 days


Coding & Compliance

CDM

01441275, 01442276


CPT Coding

81275, 81276